Letter to the Editor
Split Viewer
Blood Res 2015; 50(2):
Published online June 25, 2015
https://doi.org/10.5045/br.2015.50.2.113
© The Korean Society of Hematology
Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
1Hematology Division, Sant'Eugenio Hospital, Rome, Italy.
2Pathology Department, Sant'Eugenio Hospital, Rome, Italy.
Correspondence to : Correspondence to Pasquale Niscola. Hematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Prébet, T, Gore, SD, Esterni, B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol, 2011;29;3322-3327.
- Duong, VH, Lin, K, Reljic, T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk, 2013;13;711-715.
- Niscola, P, Tendas, A, Cupelli, L, et al. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol, 2015;133;64-66.
- Voso, MT, Breccia, M, Lunghi, M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol, 2013;90;345-348.
- Greenberg, P, Cox, C, LeBeau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997;89;2079-2088.
- Malcovati, L, Germing, U, Kuendgen, A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 2007;25;3503-3510.
- Della Porta, MG, Malcovati, L, Strupp, C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica, 2011;96;441-449.
- Maurillo, L, Buccisano, F, Del Principe, MI, et al. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis, 2013;5;e2013032.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2015; 50(2): 113-114
Published online June 25, 2015 https://doi.org/10.5045/br.2015.50.2.113
Copyright © The Korean Society of Hematology.
Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
Pasquale Niscola1*, Andrea Tendas1, Laura Scaramucci1, Marco Giovannini1, Stefano Fratoni2, and Paolo de Fabritiis1
1Hematology Division, Sant'Eugenio Hospital, Rome, Italy.
2Pathology Department, Sant'Eugenio Hospital, Rome, Italy.
Correspondence to: Correspondence to Pasquale Niscola. Hematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Prébet, T, Gore, SD, Esterni, B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol, 2011;29;3322-3327.
- Duong, VH, Lin, K, Reljic, T, et al. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk, 2013;13;711-715.
- Niscola, P, Tendas, A, Cupelli, L, et al. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol, 2015;133;64-66.
- Voso, MT, Breccia, M, Lunghi, M, et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol, 2013;90;345-348.
- Greenberg, P, Cox, C, LeBeau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997;89;2079-2088.
- Malcovati, L, Germing, U, Kuendgen, A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 2007;25;3503-3510.
- Della Porta, MG, Malcovati, L, Strupp, C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica, 2011;96;441-449.
- Maurillo, L, Buccisano, F, Del Principe, MI, et al. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. Mediterr J Hematol Infect Dis, 2013;5;e2013032.
Previous Article
